Skip to main content

Peer Review reports

From: Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis

Original Submission
15 Dec 2024 Submitted Original manuscript
20 Dec 2024 Author responded Author comments - Xing Zhong
27 Dec 2024 Reviewed Reviewer Report
23 Jan 2025 Reviewed Reviewer Report
28 Feb 2025 Author responded Author comments - Xing Zhong
Resubmission - Version 2
20 Dec 2024 Submitted Manuscript version 2
Publishing
7 Mar 2025 Editorially accepted
12 Mar 2025 Article published 10.1186/s40360-025-00898-z

You can find further information about peer review here.

Back to article page